Abstract
7TM receptors constitute one of the largest superfamilies of proteins in the human genome. They are involved in a large number of physiological and pathological processes and thus represent major and important drug targets for the pharmaceutical industry. Although the majority have been deorphanized, many remain orphan and these orphan receptors constitute a large pool of potential drug targets. This review focuses on one of these orphan targets, the Epstein-Barr Virus – induced receptor 2, EBI2 (or GPR183), together with two structurally related receptors, GPR17 and GPR18. The pharmacology and “druggability” of these three receptors are reviewed through a thorough description of their structural and functional properties and in vivo biology together with a status of currently available ligands for these receptors.
Keywords: GPCR, activation mechanism, 7TM receptors, EBI2, GPR18, GPR17, constitutive activity, deorphanization, orphan receptors, druggability, chromosomal region 13q32.3, chemogenomic analysis, pertussis toxin, –, dependent manner, phosphatidylinositol turnover, posttransplant lymphoproliferative diseases
Current Topics in Medicinal Chemistry
Title: EBI2, GPR18, and GPR17 – Three Structurally Related but Biologically Distinct 7TM Receptors
Volume: 11 Issue: 6
Author(s): Kristine Norregaard, Tau Benned-Jensen and Mette Marie Rosenkilde
Affiliation:
Keywords: GPCR, activation mechanism, 7TM receptors, EBI2, GPR18, GPR17, constitutive activity, deorphanization, orphan receptors, druggability, chromosomal region 13q32.3, chemogenomic analysis, pertussis toxin, –, dependent manner, phosphatidylinositol turnover, posttransplant lymphoproliferative diseases
Abstract: 7TM receptors constitute one of the largest superfamilies of proteins in the human genome. They are involved in a large number of physiological and pathological processes and thus represent major and important drug targets for the pharmaceutical industry. Although the majority have been deorphanized, many remain orphan and these orphan receptors constitute a large pool of potential drug targets. This review focuses on one of these orphan targets, the Epstein-Barr Virus – induced receptor 2, EBI2 (or GPR183), together with two structurally related receptors, GPR17 and GPR18. The pharmacology and “druggability” of these three receptors are reviewed through a thorough description of their structural and functional properties and in vivo biology together with a status of currently available ligands for these receptors.
Export Options
About this article
Cite this article as:
Norregaard Kristine, Benned-Jensen Tau and Marie Rosenkilde Mette, EBI2, GPR18, and GPR17 – Three Structurally Related but Biologically Distinct 7TM Receptors, Current Topics in Medicinal Chemistry 2011; 11 (6) . https://dx.doi.org/10.2174/1568026611109060618
DOI https://dx.doi.org/10.2174/1568026611109060618 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Patent Analysis as a Tool for Research Planning: Study on Natural Based Therapeutics Against Cancer Stem Cells
Recent Patents on Anti-Cancer Drug Discovery State-of-the-Art Lentiviral Vectors for Research Use: Risk Assessment and Biosafety Recommendations
Current Gene Therapy Effects of Highly Active Antiretroviral Therapy on HIV-1-Associated Oral Complications
Current HIV Research The Combination of New Immunotherapy and Radiotherapy: A N ew Potential Treatment for Locally Advanced Non-Small Cell Lung Cancer
Current Clinical Pharmacology Depression has a Strong Relationship to Alterations in the Immune, Endocrine and Neural System
Current Psychiatry Reviews Drug Targeting Approaches and Use of Drug Delivery Systems in Management of Cancer
Current Pharmaceutical Design Royal Jelly Acid, 10-Hydroxy-trans-2-Decenoic Acid, as a Modulator of the Innate Immune Responses
Endocrine, Metabolic & Immune Disorders - Drug Targets Identification of AHSA1 as a Potential Therapeutic Target for Breast Cancer: Bioinformatics Analysis and <i>in vitro</i> Studies
Current Cancer Drug Targets Current Understanding of HSP90 as a Novel Therapeutic Target: An Emerging Approach for the Treatment of Cancer
Current Pharmaceutical Design Astatine Radiopharmaceuticals: Prospects and Problems
Current Radiopharmaceuticals Ex Vivo Gene Therapy and Vision
Current Gene Therapy Development of Therapeutics for High Grade Gliomas Using Orthotopic Rodent Models
Current Medicinal Chemistry Manipulation of Glycolysis in Malignant Tumors: Fantasy or Therapy?
Current Medicinal Chemistry Redox Status in Periodontal and Systemic Inflammatory Conditions Including Associated Neoplasias: Antioxidants as Adjunctive Therapy?
Infectious Disorders - Drug Targets Targeting Drugs Against Fibroblast Growth Factor(s)-Induced Cell Signaling
Current Drug Targets Signal Transducer and Activator of Transcription 3 Signaling Pathway: A Potential Target in Sarcoma Treatment
Current Enzyme Inhibition Exploiting Internal Ribosome Entry Sites in Gene Therapy Vector Design
Current Gene Therapy Receptor Tyrosine Kinases as Therapeutic Targets in Malignant Glioma
Reviews on Recent Clinical Trials Novel Anti-Cancer Strategy in Bone Tumors by Targeting Molecular and Cellular Modulators of Bone Resorption
Recent Patents on Anti-Cancer Drug Discovery Prediction and Early Evaluation of Anticancer Therapy Response: From Imaging of Drug Efflux Pumps to Targeted Therapy Response
Current Medicinal Chemistry